市场调查报告书
商品编码
1434028
医疗保健市场中的生成式人工智慧 - 应用(个人化治疗、患者援助、患者监测和预测分析、医学影像分析和诊断、药物发现和开发)、最终用途、2024 - 2032 年全球预测Generative AI in Healthcare Market - Application (Personalized Treatment, Patient Assistance, Patient Monitoring & Predictive Analytics, Medical Image Analysis & Diagnostics, Drug Discovery & Development), End-use, Global Forecast 2024 - 2032 |
在医疗保健系统现代化计画投资不断增加的推动下,医疗保健市场中的生成式人工智慧从 2024 年到 2032 年的CAGR预计将达到 32.6%。
医疗保健提供者和领先组织正致力于透过投资人工智慧驱动的解决方案来简化流程,例如患者分诊、医学影像分析以及用于增强诊断和个人化治疗的药物发现,从而改善患者治疗结果和运营效率。例如,2023 年 10 月,美洲开发银行发放了 4,000 万美元贷款,透过扩大和改善服务基础设施和设备来增加医疗保健的可及性和有效性,以加强巴西的卫生系统。
随着医疗保健数位转型的全球趋势,在改善访问、品质和成本效益的需求的引领下,生成式人工智慧正在获得巨大的吸引力。此外,一些产业参与者正在推出创新解决方案,以满足不断变化的患者需求,进一步增强产业前景。举个例子,2023 年 12 月,Google在 MedLM 下推出了两个新的医疗保健生成人工智慧模型,为医疗保健组织在为各种工作部署人工智慧时提供灵活性。
医疗保健产业的生成式人工智慧分为应用程式、最终用途和区域。
在应用方面,患者监测和预测分析领域的市场份额预计在 2024 年至 2032 年间将达到 32.1% 的CAGR。生成式人工智慧能够即时监测患者健康资料和预测分析,从而使医疗保健提供者能够预测和预防不良事件。人工智慧驱动的演算法透过分析大量数据集来帮助识别模式和趋势,以促进早期疾病检测和个人化治疗策略。
对此类创新解决方案的需求是由对主动医疗保健管理、改善患者治疗结果和优化医疗保健资源的日益重视所推动的,进一步为行业参与者提供了潜在的成长机会。举个例子,2023 年 9 月,Oracle 推出了医疗保健生成人工智慧功能,利用语音技术增强患者互动、建立信任并改善治疗。
就最终用途而言,由于越来越多地使用生成式人工智慧解决方案来加快药物发现流程、优化临床,製药和生命科学公司领域的生成式人工智慧在医疗保健行业规模的CAGR预计从2024 年到2032 年将达到33%。试验,并开发个人化疗法。製药公司正在利用人工智慧产生的见解和预测模型来提高研发效率、降低成本并加快新疗法的上市时间。此外,产生人工智慧有助于破解复杂的生物资料,以促进精准医疗计划,从而促进该细分市场的成长。
从地区来看,到2032 年,亚太地区医疗保健产业的生成式AI 成长率预计将超过32%。随着医疗保健系统越来越拥抱科技进步,生成式AI 已成为疾病预测、药物发现和个人化治疗的变革性工具。庞大的患者群体,加上不断增长的医疗保健支出和政府促进数位医疗保健的倡议,正在加速生成式人工智慧解决方案的区域采用。例如,2023 年 9 月,埃维诺宣布在东南亚正式推出首个生成式 AI 实验室,以促进该地区的产业变革并培养当地人才。
Generative AI in Healthcare Market is set to expand at 32.6% CAGR from 2024-2032 driven by the rising investments in healthcare system modernization initiatives.
Healthcare providers and leading organizations are focusing on improving patient outcomes and operational efficiency by investing in AI-driven solutions to streamline processes, such as patient triage, medical imaging analysis, and drug discovery for enhanced diagnostics and personalized treatments. For instance, in October 2023, the Inter-American Development Bank granted a $40 million loan to strengthen Brazil's health system by increasing access and effectiveness to healthcare via the expansion and improvement of service infrastructure and equipment.
With the global trend of digital transformation in healthcare, led by the need for improved access, quality, and cost-effectiveness, generative AI is gaining significant traction. Moreover, several industry players are introducing innovative solutions for catering to the evolving patient needs, further augmenting the industry outlook. To cite an instance, in December 2023, Google launched two of its new generative AI models for healthcare under MedLM, to provide flexibility to healthcare organizations as they deploy AI for various jobs.
The generative AI in healthcare industry is segmented into application, end-use, and region.
In terms of application, the market share from the patient monitoring and predictive analytics segment is projected to record 32.1% CAGR between 2024 and 2032. Generative AI enables real-time monitoring of patient health data and predictive analytics for allowing healthcare providers to anticipate and prevent adverse events. AI-powered algorithms help identify patterns and trends by analyzing vast datasets for facilitating early disease detection and personalized treatment strategies.
The demand for such innovative solutions is driven by the increasing emphasis on proactive healthcare management, improved patient outcomes, and the optimization of healthcare resources, further offering potential growth opportunities to the industry participants. To cite an instance, in September 2023, Oracle launched healthcare-generative AI capabilities to leverage speech technology to enhance patient interaction, develop trust, and improve treatment.
In terms of end-use, the generative AI in healthcare industry size from the pharmaceutical and life science companies segment is set to witness 33% CAGR from 2024-2032 attributed to the increasing use of generative AI solutions to expedite drug discovery processes, optimize clinical trials, and develop personalized therapies. Pharmaceutical firms are harnessing AI-generated insights and predictive modeling to enhance R&D efficiency, reduce costs, and accelerate time-to-market for novel treatments. Additionally, generative AI aids in deciphering complex biological data for facilitating precision medicine initiatives, contributing to the segment growth.
Regionally, the Asia Pacific generative AI in healthcare industry is slated to depict over 32% growth rate through 2032. Generative AI has emerged as a transformative tool for disease prediction, drug discovery, and personalized treatment with healthcare systems increasingly embracing technological advancements. The large patient population, coupled with the rising healthcare expenditure and government initiatives for promoting digital healthcare is accelerating the regional adoption of generative AI solutions. For instance, in September 2023, Avanade announced the official debut of its first Generative AI Lab in Southeast Asia for enabling industrial change and developing local talent in the region.